Opens in a new tab

Insurers make unequal decisions on cancer drug coverage

Wednesday 18th November 2026 on 13:15 in Switzerland

cancer care, health insurance, Switzerland

Swiss cancer patients can receive different coverage decisions for the same off-label treatment depending on their insurer, according to an SRF report.

Pascal Rolle was diagnosed with an aggressive form of blood cancer in 2023. His oncologist sought approval for Elzonris, an innovative treatment not officially authorised for the use proposed. The medicine costs several hundred thousand francs, and Rolle’s insurer initially refused to cover it. With a lawyer’s help, he challenged the decision and received treatment seven months later. His cancer is now regressing.

Nearly 80,000 requests for innovative off-label medicines are submitted in Switzerland each year, and the costs are not automatically covered. One in three cancer patients needs such medicines, according to the report. Insurers assess requests individually.

A 2020 study by the Swiss Federal Office of Public Health found significant differences between insurers: some approved almost all requests, while others rejected more than half. The study did not identify insurers by name. After five years and a case before the administrative court, RTS obtained the data under freedom-of-information rules.

The insurers questioned the study and whether their results could be compared, saying cases had not been assessed consistently. Sanitas was the only insurer to request a correction, arguing that the study counted treatment trials as rejections and had therefore disadvantaged the company. It said its actual approval rate was 80 percent. The industry association Prio Swiss also raised “serious reservations” about the comparability of the figures.

The study’s authors said differences in how insurers’ medical advisers assessed cases were a key reason for the variation. A reform took effect in 2024 to standardise procedures and reduce costs for off-label treatments. Prio Swiss says the problem has been resolved and believes a current study would find no significant differences.

However, oncologists say disparities persist. Solange Peters, head of oncology at Lausanne University Hospital, shared the hospital’s figures with RTS. From 2020 to 2025, insurers’ approval rates for the hospital’s applications varied by more than 20 percentage points, she said. Peters said the same insurers remained the “winners and losers” after the reform.

This month, two of her patients with pancreatic cancer received opposite decisions on coverage, despite having the same illness, medication and medical justification.

Source 
(via SRF)